ResearcherKansai Medical UniversityActive in the last 2 years
Takako Ooshio
Matched on ORCID iD 0000-0001-6508-8152; OpenAlex author ID A5042205540. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 5
- Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. First author DOI 10.1111/cas.70522↗
- Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ymthe.2025.05.037↗
- Identifying simultaneous inhibition of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic cancer Co-author DOI 10.1101/2024.10.23.619807↗
- Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16100↗
- Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3762↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Masahiro Sonoshita · 5 shared papers, 2023–2026 · strength 1.01
- Paper Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. DOI 10.1111/cas.70522↗
- Paper Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. DOI 10.1016/j.ymthe.2025.05.037↗
- Paper Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. DOI 10.1111/cas.16100↗
- Ryodai Yamamura · 4 shared papers, 2023–2026 · strength 0.84
- Paper Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. DOI 10.1111/cas.70522↗
- Paper Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. DOI 10.1016/j.ymthe.2025.05.037↗
- Paper Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma. DOI 10.1111/cas.16100↗
- Hui Jiang · 3 shared papers, 2024–2026 · strength 0.68
- Paper Genotype-Informed Whole-Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC. DOI 10.1111/cas.70522↗
- Paper Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. DOI 10.1016/j.ymthe.2025.05.037↗
- Paper Identifying simultaneous inhibition of riboflavin metabolism and MEK as a novel therapeutic strategy for pancreatic can… DOI 10.1101/2024.10.23.619807↗
- Han Hai · 2 shared papers, 2025–2026 · strength 0.50
- Sho Sekiya · 2 shared papers, 2023–2024 · strength 0.34
- Junki Fukuda · 2 shared papers, 2023–2024 · strength 0.34
- Toru Nakamura · 2 shared papers, 2023–2024 · strength 0.34
- Satoshi Hirano · 2 shared papers, 2023–2024 · strength 0.34
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.